Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD

Authors:

Abstract
No abstract available
Funding Information
  • National Institutes of Health
  • NIH
  • Sunovion
  • National Heart, Lung, and Blood Institute (HHSN268200900017C, U01 HL137880, U24 HL141762)
  • Theravance Biopharma US
  • Boehringer Ingelheim
  • Bayer Fund
  • GlaxoSmithKline
  • Bellerophon Therapeutics
  • Forest Research Institute
  • Takeda Pharmaceutical Company
  • COPD Foundation

This publication has 48 references indexed in Scilit: